Utah Cord Bank (UCB), the producer of StemShot® and StemVive®, is an experienced and innovative company dedicated to providing the highest quality bioactive stem cell stimulating products for use in regenerative medicine. Our mission is to assist medical professionals increase the productivity of their practices by providing information and therapeutic products to better meet the needs of their patients. Our scientists, technicians, and sales personnel are here to provide information you need.
WE ARE COMMITTED TO PROVIDING CUTTING-EDGE TECHNOLOGY IN REGENERATIVE MEDICINE
UCB was founded as an umbilical cord blood bank in 2005 at a time of escalating scientific advances in cell biology and advanced regenerative medicine. Using these advances, UCB chief scientist and founder, Eliott D. Spencer, PhD (Biochemistry, Brigham Young University, 2002), developed innovative protocols to harvest bioactive ingredients including stem cells from birth tissues and provide minimally-manipulated stem cell-based products of the highest quality. UCB continues to innovate with a constant focus on product improvement. For example, UCB was the first lab to develop a minimally-manipulated and highly concentrated allograft flowable formula specifically configured for delivery in a homologous manner for conditions where particulate matrix is contraindicated. Scaffolding is sacrificed for more growth factors and cell yield for this use protocol. Tomorrow’s products must be better than today’s!
UCB complies with all requirements and standards established by the FDA (Federal Drug Administration). We have a successful history with FDA inspections and are pleased to provide products of the highest standards in the industry using state-of-the-art technology. StemShot® and StemVive® are processed from donated human tissue from full term deliveries and are regulated as a Human Cell, Tissue, or Cellular or Tissue-Based Product (HCT/P) under 21 CFR Part 1271 and Section 361 of the Public Health Service Act. The StemShot® sales and marketing team are committed to helping you expand the productivity of your practice by delivering the best in product information as well as friendly, helpful, & integrous customer service.
UCB is currently in the process of initiating the pursuit an RMAT (Regenerative Medicine Advanced Therapy) designation which will allow early interaction with the FDA to innovate product development and usage. Once an RMAT is approved, the FDA can permit fulfillment of post-approval requirements under accelerated approval through the submission of clinical evidence, clinical studies, patient registries, or other sources of real world evidence to help make these exciting, paradigm changing new therapies available to those in need.
The RMAT designation for a bio-engineered product applies if the biologic is intended to treat serious or life-threatening diseases or conditions and if there is preliminary clinical evidence indicating that the biologic has the potential to address unmet medical needs for a given disease or condition.
Also, UCB is pursuing an in depth analysis of the bioactive molecular components contained in StemShot and StemVive in a noted GMP laboratory to detail as much as possible the restorative components, such as growth factors, Cytokins, Exosomes and micro-RNA, etc.